KorrekturOpen Access · CC BY 4.0
Correction to “Targeting T Cell–Mediated Inflammation: Clinical Benefits of Lifitegrast in Improving Symptoms and Signs of Dry Eye Disease”
Journal of Ophthalmology · 2026-01 · 2026 (1)
DOI: 10.1155/joph/9857150 ↗Kurz gefasst
Korrektur in der Zeitschrift Journal of Ophthalmology, online erschienen am 05.11.2026. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
[This corrects the article DOI: 10.1155/joph/9973882.].
Zitieren
APA
(2026). Correction to “Targeting T Cell–Mediated Inflammation: Clinical Benefits of Lifitegrast in Improving Symptoms and Signs of Dry Eye Disease”. Journal of Ophthalmology, 2026(1). https://doi.org/10.1155/joph/9857150
Vancouver
Correction to “Targeting T Cell–Mediated Inflammation: Clinical Benefits of Lifitegrast in Improving Symptoms and Signs of Dry Eye Disease”. Journal of Ophthalmology. 2026;2026(1). doi:10.1155/joph/9857150
BibTeX
@article{euvimed2026,
title = {Correction to “Targeting T Cell–Mediated Inflammation: Clinical Benefits of Lifitegrast in Improving Symptoms and Signs of Dry Eye Disease”},
journal = {Journal of Ophthalmology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/joph/9857150}
}
EUVIMED